Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03757052
Other study ID # 2019-4379
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 20, 2018
Est. completion date June 2020

Study information

Verified date March 2019
Source CHU de Quebec-Universite Laval
Contact Jean-Philippe Drolet, MD FRCPC
Phone 418-525-4444
Email jean-philippe.drolet@chudequebec.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

False diagnosis of penicillin allergy are frequently reported, and have been proven detrimental to patients. Current guidelines for the assessment of drug allergies recommend that penicillin allergy be evaluated first with prick and intradermal skin tests, and then completed with a graded oral challenge, spread over at least two doses. However, it has been shown that these skin tests, in addition to consuming resources and time, are of limited, or even doubtful validity, given the poor predictive values that have been reported in the modern penicillins era. It now seems unreasonable to continue their use without addressing other, more efficient diagnostic stategies. Several groups have now demonstrated the safety, validity, and efficiency of a direct, two-step amoxicillin oral challenge (starting with 10% of the standard therapeutic dose, followed by 90 % of the dose), without prior skin tests, first for any type of reaction in the pediatric population, then for any non-immediate reaction in the adult population. The objective of this study is to demonstrate the safety, efficiency, and validity of direct, two-step graded oral challenge with amoxicillin for the evaluation of any reported penicillin allergy in the adult population, excluding high-risk patients (documented anaphylaxis to a penicillin in the last 5 years). Skin tests will first be performed according to the protocol currently in use at the CHUL, then consented patients will proceed with the graded oral challenge still according to the protocol currently in use at the CHUL, but regardless of the skin tests results. The results of the two tests will be compared to determine the safety, efficiency and validity of proceeding directly to the graded oral challenge.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date June 2020
Est. primary completion date April 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Being 18 years of age or older at the time of the test

- Being referred by a health professional for the evaluation of any allergic reaction to a penicillin, including natural penicillins, anti-staphylococcal penicillins, aminopenicillins, penicillins combined with a beta-lactamase inhibitor, and carboxypenicillins ; or an antibiotic of the beta-lactam family, whose assessment requires testing for penicillins, according to the treating allergist

Exclusion Criteria:

- Pregnancy

- Poorly controlled asthma, chronic lung disease or heart disease

- Failure to stop beta-blockers prior to the test

- Occurrence of the reaction in the 4 weeks preceding the test (possibility of false negatives)

- History of severe delayed hypersensitivity reaction, reaction requiring hospitalization of more than 24 hours, or bullous, pustular, exfoliative or mucosal reaction (excluding angioedema)

- Recent anaphylaxis (<5 years), defined as concomitant involvement of at least two systems (respiratory, digestive, mucocutaneous or cardiovascular) within one hour of administration of the drug

Study Design


Intervention

Diagnostic Test:
Penicillin Skin Testing
Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.

Locations

Country Name City State
Canada CHU de Quebec Quebec city Quebec

Sponsors (1)

Lead Sponsor Collaborator
CHU de Quebec-Universite Laval

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Type 1 Hypersensitivity Reaction The primary outcome is the occurrence of immediate hypersensitivity symptoms, occuring during the test period, which is up to 60 minutes after the last dose of amoxicillin. 60 minutes
Secondary Skin Tests Results Concordance of Skin Tests Results with Oral Challenge Results 60 minutes
Secondary Severity of immediate hypersensitivity symptoms Mild, moderate and severe 60 minutes
Secondary Delayed hypersensitivity symptoms Occurrence of delayed hypersensitivity symptoms 14 days
See also
  Status Clinical Trial Phase
Terminated NCT05563610 - Oral Penicillin Challenge and Allergy De-labeling in Children Phase 4
Completed NCT05020327 - Inpatient Penicillin Allergy Delabeling Study Phase 4
Completed NCT04441021 - Feasibility Assessment of Risk Stratification and Oral Challenge in Hospitalized Children at Low Risk for Antibiotic Allergy
Not yet recruiting NCT05956080 - Penicillin Allergy Delabeling Among Surgical Patients N/A
Completed NCT03702270 - The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal N/A
Recruiting NCT05464615 - Geisinger Antibiotic Allergy Pilot Program: Assess and Address Early Phase 1
Completed NCT03702283 - Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal in ICU Setting N/A
Not yet recruiting NCT03499457 - Penicillin Allergy in Shfayim Clinic N/A
Completed NCT01667055 - The Diagnosis of Beta-lactam Hypersensitivity in Thailand
Withdrawn NCT00589251 - Equivalency of Penicilloate Skin Test Reactivity Prepared by a Modified Alkaline Hydrolysis Technique N/A
Completed NCT04620746 - Penicillin Allergy Testing in STD Clinics Phase 4
Completed NCT05090527 - Penicillin Allergy Delabeling Project N/A
Completed NCT03033394 - Beta-lactam Pharmacokinetics in Secondary Care
Completed NCT02036840 - Perioperative Antibiotic Choices for Surgical Prophylaxis in Penicillin-allergic Pediatric Patients N/A
Terminated NCT00363688 - Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin Phase 4
Completed NCT03158831 - Drug Challenges Without Prior Skin Testing Phase 1
Recruiting NCT06303128 - Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge Phase 3
Completed NCT03942731 - Penicillin Allergy Testing and Resensitization Rate
Completed NCT05010304 - Penicillin De-labeling in the Pediatric Primary Care Setting Phase 4
Completed NCT03404804 - Oral Challenge in the Pediatric ED Phase 4